AstraZeneca and Daiichi Sankyo to jointly develop cancer drug
In This Article:
March 28 (Reuters) - British drugmaker AstraZeneca Plc said late on Thursday it entered into a collaboration deal with Daiichi Sankyo Co Ltd of Japan to develop trastuzumab deruxtecan, a proprietary antibody-drug conjugate for cancer treatment.
Under the terms of the deal, AstraZeneca will pay Daiichi Sankyo up to $6.90 billion in total consideration, including $1.35 billion in upfront payment, Daiichi said in a separate statement. (Reporting by Bhargav Acharya in Bengaluru; Editing by Sandra Maler)
Terms and Privacy Policy